Purchase this mini-database of 7 companies working with γδ T-cell targeting antibodies
Antibodies are used in a wide variety of therapies. Lately several companies have begun utilizing antibodies to promote the anti-tumor activity of γδ T-cells. Bispecific antibodies are an effective tool for mediating tumor killing as they can be programmed to recruit T-cells to target tumors. The most conventional use of this technology is bispecific T-cell engagers also known as BiTEs. BiTEs usually are able to recruit T-cells to engage the tumor by binding the CD3 as well as a surface antigen on the tumor such as CD19 found on lymphoma and leukemia cells.
Studies have shown that bispecific antibodies are effective at recruiting γδ T-cells to target cancers such as pancreatic ductal adenocarcinoma. Companies are currently working on revolutionary new ways of engaging γδ T-cells by the use of antibodies. With the γδ T-cell Targeting Antibodies Companies by Stargazing Bio Research, you will get an up to date overview of all the companies currently working on developing and perfecting this technology at the forefront of therapeutic biotech.